Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 3/20 | 1.00 |
| ▸ | RIPK2 | O43353 | 2/20 | 1.00 |
| ▸ | RAF1 | P04049 | 2/20 | 1.00 |
| ▸ | KDR | P35968 | 2/20 | 1.00 |
| ▸ | MAP2K2 | P36507 | 2/20 | 1.00 |
| ▸ | TGFBR2 | P37173 | 2/20 | 1.00 |
| ▸ | NEK2 | P51955 | 2/20 | 1.00 |
| ▸ | MAP2K1 | Q02750 | 2/20 | 1.00 |
| ▸ | TNK2 | Q07912 | 2/20 | 1.00 |
| ▸ | MAP2K5 | Q13163 | 2/20 | 1.00 |
| ▸ | PTK6 | Q13882 | 2/20 | 1.00 |
| ▸ | NEK11 | Q8NG66 | 2/20 | 1.00 |
| ▸ | MAP3K20 | Q9NYL2 | 2/20 | 1.00 |
| ▸ | MAP4K5 | Q9Y4K4 | 2/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 1/20 | 1.00 |
| ▸ | EGFR | P00533 | 1/20 | 1.00 |
| ▸ | KRAS | P01116 | 1/20 | 1.00 |
| ▸ | PGR | P06401 | 1/20 | 1.00 |
| ▸ | RET | P07949 | 1/20 | 1.00 |
| ▸ | CHRM2 | P08172 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Vemurafenib SCHEMBL298931 | 1.00 | BRAF (1.00) | BRAFRIPK2RAF1KDRMAP2K2 | |
| Vemurafenib SCHEMBL29356185 | 1.00 | BRAF (1.00) | BRAFRIPK2RAF1KDRMAP2K2 | |
| Vemurafenib SCHEMBL29355460 | 1.00 | BRAF (1.00) | BRAFRIPK2RAF1KDRMAP2K2 | |
| Vemurafenib SCHEMBL17784481 | 0.95 | BRAF (0.91) | BRAFRIPK2RAF1KDRMAP2K2 | |
| SCHEMBL298368 | 0.95 | BRAF (0.91) | BRAFRIPK2RAF1KDRMAP2K2 | |
| SCHEMBL19575141 | 0.94 | BRAF (0.89) | BRAFRIPK2RAF1KDRMAP2K2 | |
| SCHEMBL298927 | 0.94 | BRAF (0.89) | BRAFRIPK2RAF1KDRMAP2K2 | |
| SCHEMBL7876722 | 0.94 | BRAF (0.89) | BRAFRIPK2RAF1KDRMAP2K2 | |
| SCHEMBL20408711 | 0.94 | BRAF (0.88) | BRAFRIPK2RAF1KDRMAP2K2 | |
| SCHEMBL293053 | 0.93 | CYP2C19 (1.00) | BRAFRIPK2RAF1KDRMAP2K2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10414764-B2 | Substantially pure vemurafenib and its salts | SHILPA MEDICARE LIMITED | 2019-09-17 | — | — | US | disclosed |
| US-20170320872-A1 | SUBSTANTIALLY PURE VEMURAFENIB AND ITS SALTS | SHILPA MEDICARE LIMITED (IN) | 2017-11-09 | — | — | US | disclosed |
| US-20170320872-A1 | SUBSTANTIALLY PURE VEMURAFENIB AND ITS SALTS | SHILPA MEDICARE LIMITED (IN) | 2017-11-09 | — | — | US | disclosed |
| WO-2015075749-A1 | NOVEL PROCESSES FOR THE PREPARATION OF VEMURAFENIB | LAURUS LABS PRIVATE LIMITED (IN) | 2015-05-28 | — | — | WO | disclosed |
| US-8741920-B2 | Process for the manufacture of pharmaceutically active compounds | HOFFMANN-LA ROCHE, INC. (US) | 2014-06-03 | — | — | US | disclosed |
| US-8741920-B2 | Process for the manufacture of pharmaceutically active compounds | HOFFMANN-LA ROCHE, INC. (US) | 2014-06-03 | — | — | US | disclosed |
| US-8530661-B2 | Process for the manufacture of pharmaceutically active compounds | HOFFMANN-LA ROCHE, INC. (US) | 2013-09-10 | — | — | US | disclosed |
| US-20130005761-A1 | PROCESS FOR THE MANUFACTURE OF PHARMACEUTICALLY ACTIVE COMPOUNDS | HOFFMANN-LA ROCHE INC. | 2013-01-03 | — | — | US | disclosed |
| US-20130005978-A1 | PROCESS FOR THE MANUFACTURE OF PHARMACEUTICALLY ACTIVE COMPOUNDS | HILDBRAND STEFAN (CH) | 2013-01-03 | — | — | US | disclosed |
| US-8329724-B2 | Process for the manufacture of pharmaceutically active compounds | HOFFMANN-LA ROCHE INC. (US) | 2012-12-11 | — | — | US | disclosed |
| WO-2011015522-A2 | PROCESS FOR THE MANUFACTURE OF PHARMACEUTICALLY ACTIVE COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2011-02-10 | — | — | WO | disclosed |
| US-20110028511-A1 | PROCESS FOR THE MANUFACTURE OF PHARMACEUTICALLY ACTIVE COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2011-02-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110028511-A1 | PROCESS FOR THE MANUFACTURE OF PHARMACEUTICALLY ACTIVE COMPOUNDS | CYP2F1, CYP1B1, CYP7A1 | BRAF 2744/4885RIPK2 4164/4885RAF1 1134/4885 |
| US-20130005978-A1 | PROCESS FOR THE MANUFACTURE OF PHARMACEUTICALLY ACTIVE COMPOUNDS | CYP4B1, PCSK9, CYP1B1 | BRAF 2242/4885RIPK2 4515/4885RAF1 1555/4885 |
| US-20130005761-A1 | PROCESS FOR THE MANUFACTURE OF PHARMACEUTICALLY ACTIVE COMPOUNDS | CYP1B1, CYP4B1, CYP2C19 | BRAF 3167/4885RIPK2 4586/4885RAF1 1957/4885 |
| US-20170320872-A1 | SUBSTANTIALLY PURE VEMURAFENIB AND ITS SALTS | BRAF, RAF1, NRAS | BRAF 1/4885RIPK2 3219/4885RAF1 2/4885 |
| US-10414764-B2 | Substantially pure vemurafenib and its salts | BRAF, RAF1, NRAS | BRAF 1/4885RIPK2 3219/4885RAF1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.